



דצמבר 2025

רופא/ה, רוקח/ת נכבד/ה,

חברת רז רוקחות מבקשת להודיעכם על עדכון העלון לרופא של התכשיר:

RIPOL 10 MG/ML
ריפול 10 מ"ג/מ"ל
Emulsion for injection or infusion (I.V)

המרכיב הפעיל:

PROPOFOL 10 MG/ML

התוויה מאושרת:

Ripol 10 mg/ml is a short-acting intravenous general anaesthetic for:

- Induction and maintenance of general anaesthesia in adults and paediatric patients > 1 month of age
- Sedation for diagnostic and surgical procedures, alone or in combination with local or regional anaesthesia in adults and paediatric patients > 1 month of age
- Sedation of ventilated patients > 16 years of age in the intensive care unit

בהודעה זו מצוינים רק הסעיפים בהם נעשו שינויים מהותיים בעלון לרופא. שינויים בעלון המהווים החמרה מודגשים ברקע צהוב.

העלון לרופא מפורסם במאגר התרופות שבאתר משרד הבריאות (www.health.gov.il), וניתן גם לקבלו מודפס ע"י פניה לבעל הרישום:
רז רוקחות בע"מ, רחוב גשר העץ 31, פארק תעשיות עמק חפר ובטלפון 04-9079710.

בברכה,

רז רוקחות בע"מ



[...]

4.5 Interaction with other medicinal products and other forms of interaction

RIPOL 10MG/ML has been used in association with spinal and epidural anaesthesia and with commonly used premedicants, neuromuscular blocking drugs, inhalational agents and analgesic agents; no pharmacological incompatibility has been encountered. Lower doses of RIPOL 10MG/ML may be required where general anaesthesia is used as an adjunct to regional anaesthetic techniques. Profound hypotension has been reported following anaesthetic with propofol in patients treated with rifampicin.

The concurrent administration of other CNS depressants such as pre-medication drugs, inhalation agents, analgesic agents may add to the sedative, anaesthetic and cardiorespiratory depressant effects of RIPOL 10MG/ML (see Section 4.4).

A need for lower propofol doses has been observed in patients taking valproate. When used concomitantly, a dose reduction of propofol may be considered.

A need for lower propofol doses has been observed in patients taking midazolam. The coadministration of propofol with midazolam is likely to result in enhanced sedation and respiratory depression. When used concomitantly, a dose reduction of propofol should to be considered.

Co-administration with dexmedetomidine is likely to lead to an enhancement of effects. Propofol dose required for sedation may have to be reduced in the presence of dexmedetomidine.

[...]